Title:
PD-1 VARIANT HAVING IMPROVED BINDING TO PD-L1
Document Type and Number:
WIPO Patent Application WO/2019/151771
Kind Code:
A1
Abstract:
The present invention relates to a PD-1 variant having improved binding to PD-L1. In addition, the present invention relates to a method for producing and a method for screening for the PD-1 variant. A PD-1 variant of the present invention effectively inhibits binding between wild-type PD-1 and PD-L1, and thus can be expected to have penetration power and an effect of cancer death by immunocytes or a treatment effect on infectious diseases, which are far greater than those of conventional therapeutic agents for immune checkpoint inhibition and, simultaneously, can minimize the possibility of immunogenicity occurrence and, further, can promote the convenience of developing biological pharmaceutical drugs through the implementation of aglycosylation.
Inventors:
JUNG SANG TAEK (KR)
CHUN KWANG-JIN (KR)
HA JI YEON (KR)
CHUN KWANG-JIN (KR)
HA JI YEON (KR)
Application Number:
PCT/KR2019/001290
Publication Date:
August 08, 2019
Filing Date:
January 30, 2019
Export Citation:
Assignee:
NEURACLE GENETICS INC (KR)
International Classes:
C07K14/705; A61K38/00; A61P31/00; A61P35/00; A61P37/04; C12N15/10
Domestic Patent References:
| WO2017200796A1 | 2017-11-23 |
Foreign References:
| EP2638061B1 | 2015-04-22 | |||
| KR20160113113A | 2016-09-28 |
Other References:
LIU, C. ET AL.: "Soluble PD-1 aggravates progression of collagen-induced arthritis through Th and Th17 pathways", ARTHRITIS RESEARCH & THERAPY, vol. 17, no. 340, 25 November 2015 (2015-11-25), pages 1 - 13, XP055628020
LIANG, Z. ET AL.: "High-affinity human PD-L1 variants attenuate the suppression of T cell activation", ONCOTARGET, vol. 8, no. 5 1, 10 October 2017 (2017-10-10), pages 88360 - 88375, XP002787425, doi:10.18632/oncotarget.21729
See also references of EP 3747897A4
J. NAIDOO ET AL., ANNALS OF ONCOLOGY, 2015
LUCIA GELAO ET AL., TOXINS, 2014
GORGE K. PHILIPS ET AL., INTERNATIONAL IMMUNOLOGY, 2015
MANIATIS ET AL.: "Molecular Cloning, A Laboratory Manual", 1988, COLD SPRING HARBOR PRESS
AUSUBEL ET AL.: "Current Protocols in Molecular Biology", 1994, JOHN, WILEY & SONS, INC.
"Remington's Pharmaceutical Sciences", 1995
LIANG, Z. ET AL.: "High-affinity human PD-L1 variants attenuate the suppression of T cell activation", ONCOTARGET, vol. 8, no. 5 1, 10 October 2017 (2017-10-10), pages 88360 - 88375, XP002787425, doi:10.18632/oncotarget.21729
See also references of EP 3747897A4
J. NAIDOO ET AL., ANNALS OF ONCOLOGY, 2015
LUCIA GELAO ET AL., TOXINS, 2014
GORGE K. PHILIPS ET AL., INTERNATIONAL IMMUNOLOGY, 2015
MANIATIS ET AL.: "Molecular Cloning, A Laboratory Manual", 1988, COLD SPRING HARBOR PRESS
AUSUBEL ET AL.: "Current Protocols in Molecular Biology", 1994, JOHN, WILEY & SONS, INC.
"Remington's Pharmaceutical Sciences", 1995
Attorney, Agent or Firm:
CHUNG HYUN PATENT & LAW FIRM (KR)
Download PDF:
Previous Patent: METHOD FOR PREPARING NATURAL L-CYSTEINE CRYSTALS BY CONTINUOUS CHROMATOGRAPHY
Next Patent: CAMERA MODULE
Next Patent: CAMERA MODULE